Kraig Biocraft Laboratories (OTC: KBLB) is a biotechnology company that develops recombinant spider silk fibers using genetically engineered silkworms. The company inserts spider silk protein gene sequences into silkworm embryos to produce high-strength, lightweight fibers intended for commercial textile and technical applications. Target end markets include performance apparel, workwear, filtration, luxury fashion, medical textiles, geotextiles, and ballistic-resistant materials. As of the fiscal year ended December 31, 2025, the company reported zero revenue, funding operations through equity sales under a Standby Equity Purchase Agreement (SEPA) and proceeds from the sale of a gold bullion investment ($443,437 in FY2025). The company holds patents issued across Vietnam, South Korea, Australia, Canada, France, and Germany, derived in part from a joint development program with the University of Notre Dame. Kraig Labs operates research and production infrastructure in Vietnam. The company is pre-commercial, carrying an accumulated deficit, and has relied on stock issuances and debt instruments to finance operations through at least December 31, 2025.

Revenue model

No product revenue as of FY2025 (December 31, 2025). The company has financed operations through equity issuances, including $2,602,900 in stock sale proceeds in FY2025, and a SEPA facility with a third-party investor. Additional cash in FY2025 came from the sale of a gold bullion investment ($443,437 net proceeds).

Products and services

Recombinant spider silk fiber produced via transgenic silkworms. Applications include performance apparel, workwear, filtration, luxury fashion, medical textiles, geotextiles, and ballistic-resistant materials. No commercial products were generating revenue as of December 31, 2025.

Customers and end markets

No commercial customers as of December 31, 2025. Target end markets include technical textiles, performance apparel, workwear, filtration, luxury fashion, medical textiles, geotextiles, and ballistic protection. The company is in pre-commercial development stage.

Value-chain role

Upstream biotechnology developer and fiber producer. Kraig Labs conducts genetic engineering research, breeds transgenic silkworms, and produces spider silk fiber intended for downstream textile manufacturers. The company holds exclusive global commercial rights to jointly developed technologies from the University of Notre Dame and operates its own R&D and production facility in Vietnam.

Geographic exposure

Research and development facility opened in 2017 (location unspecified in excerpts). Production and operational presence in Vietnam. Patents issued in Vietnam, South Korea, Australia, Canada, France, and Germany as of the filing date (2026-03-30). Incorporated in Wyoming.

Source: SEC 10-K, filed 2026-03-30

Industry: Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) Peers: Basanite Inc Sisecam Resources LP Core Molding Technologies Inc Dow Inc Greystone Logistics Inc Tredegar Corp Zymergen Inc.